ArticleVirologica Sinica2023
Characterization of bacteriophage BUCT631 lytic for K1 Klebsiella pneumoniae and its therapeutic efficacy in Galleria mellonella larvae.
Article in Virologica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 34 citations in OpenAlex.
- Identification and Genomic Characterization of a Novel Teseptimavirus Species (vB_EcoP_S37A) and a Mosigvirus Phage (vB_EcoM_S37) Infecting Swine Extraintestinal PathogenicVeterinary sciences · 2026Article
- Zinc oxide-bacteriophage synergistic combination for dual-mode antibacterial activity against multidrug-resistant Escherichia coli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Unraveling a new Klebsiella phage KP47 against Klebsiella spp.BMC microbiology · 2026Article
- Characterization of a novel phage BUCT800 against Acinetobacter baumannii and its biofilm removal efficiency.Archives of virology · 2026Article
- Characterization and complete genomic sequence of a novel phage BUCT805 infectingMicrobiology spectrum · 2026Article
- Isolation and characterization of novel bacteriophages with broad-spectrum lytic activity against carbapenem-resistant Klebsiella pneumoniae capsular pathotypes K1, K2, K3, K5, and K20.Biology direct · 2026Article
- Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae.Archives of virology · 2026Article
- Biological characterization and genomic analysis of Kpp-61, a lytic bacteriophage against K1-type Klebsiella pneumoniae.Archives of virology · 2026Article
- Characterization of the bacteriophage vB_KpnP_Henu1_3 lytic for K1Microbiology spectrum · 2026Article
- Protective effects of recombinant depolymerase Dep44 against K64-CRKP-induced pulmonary infection in a murine infection model.BMC microbiology · 2026Article
- Multidimensional characterization of a novel porcine Klebsiella pneumoniae phage Pkp-1.BMC microbiology · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- YZ462 exhibits potent antibacterial activity against methicillin-resistant Staphylococcus aureus through bacterial membrane disruption.BMC microbiology · 2025Article
- Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii.Virologica Sinica · 2025Article
- Characterization and genomics of phage Henu2_3 against K1 Klebsiella pneumoniae and its efficacy in animal models.AMB Express · 2025Article
- Characterization and Complete Genomic Analysis of a Novel Bacteriophage BUCT775 forInternational journal of molecular sciences · 2025Article
- The virulent bacteriophage Henu8 as an antimicrobial synergist againstMicrobiology spectrum · 2025Article
- Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe infections caused by multidrug-resistant Klebsiella pneumoniae (K. pneumoniae) highlight the need for new therapeutics with activity against this pathogen. Phage therapy is an alternative treatment approach for multidrug-resistant K. pneumoniae infections. Here, we report a novel bacteriophage (phage) BUCT631 that can specifically lyse capsule-type K1 K. pneumoniae. Physiological characterization revealed that phage BUCT631 could rapidly adsorb to the surface of K. pneumoniae and form an obvious halo ring, and it had relatively favorable thermal stability (4-50 °C) and pH tolerance (pH = 4-12). In addition, the optimal multiplicity of infection (MOI) of phage BUCT631 was 0.01, and the burst size was approximately 303 PFU/cell. Genomic analysis showed that phage BUCT631 has double-stranded DNA (total length of 44,812 bp) with a G + C content of 54.1%, and the genome contains 57 open reading frames (ORFs) and no virulence or antibiotic resistance related genes. Based on phylogenetic analysis, phage BUCT631 could be assigned to a new species in the genus Drulisvirus of the subfamily Slopekvirinae. In addition, phage BUCT631 could quickly inhibit the growth of K. pneumoniae within 2 h in vitro and significantly elevated the survival rate of K. pneumoniae infected Galleria mellonella larvae from 10% to 90% in vivo. These studies suggest that phage BUCT631 has promising potential for development as a safe alternative for control and treatment of multidrug-resistant K. pneumoniae infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.